Safety & Availability (Biologics)
Image
This webpage was developed to provide the public with important information about the safety and availability of biological products.
Safety communications older than 2017 are available on FDA Archive.
Biologics Safety and Availability Communications
- 2026 Safety and Availability Communications
- 2025 Safety and Availability Communications
- 2024 Safety and Availability Communications
- 2023 Safety and Availability Communications
- 2022 Safety and Availability Communications
- 2021 Safety and Availability Communications
- 2020 Safety and Availability Communications
- 2019 Safety and Availability Communications (Archived)
- 2018 Safety and Availability Communications (Archived)
- 2017 Safety and Availability Communications (Archived)
Related Information
- MedWatch: The FDA Safety Information and Adverse Event Reporting Program
- Letters to Industry / Healthcare Providers / Clinical Investigators (Archived)
- Bovine Spongiform Encephalopathy (BSE)
- FDA's Sentinel Initiative
- CBER Biologics Effectiveness and Safety (BEST) System
Sub-Topic Paragraphs
Paragraph Header
Contact Us
Paragraph Header
Contact Us
Contact Point
1-888-INFO-FDA
1-888-463-6332
Hours Available
Food and Drug Administration
Food and Drug Administration
White Oak Campus
White Oak Campus
10903 New Hampshire Ave
Silver Spring, MD 20993
United States
For Latest Updates Follow
Contact Point Twitter
@FDADrugs
The latest information from the Center for Biologics Evaluation and Research.